Navigation Links
Jazz Pharmaceuticals, Inc. Announces Final Patient Has Completed Phase III Clinical Trial of Sodium Oxybate to Treat Fibromyalgia
Date:9/11/2008

wo pivotal Phase III trials.

Sodium oxybate is the active ingredient in Xyrem(R), a Jazz Pharmaceuticals product approved by the FDA for the treatment of excessive daytime sleepiness and cataplexy (the sudden loss of muscle tone) in patients with narcolepsy. Sodium oxybate has not been approved for the treatment of fibromyalgia.

About Fibromyalgia

Fibromyalgia is a chronic pain syndrome defined by widespread pain lasting at least three months. According to the American College of Rheumatology, between two and four percent of the U.S. population suffers from fibromyalgia. Fibromyalgia is believed to be a central nervous system condition. In addition to pain, fibromyalgia patients often suffer from a combination of muscle stiffness, fatigue, disturbed sleep, restless legs syndrome and impaired memory and concentration. Although physicians do not understand the cause of fibromyalgia, it may be triggered by physical trauma, emotional stress or infection. The criteria established by the American College of Rheumatology for the classification of fibromyalgia require the application of pressure at 18 different points on the body and measurement of pain induced by such pressure. If at least 11 of the 18 points are painful and have been painful for three months, the patient is diagnosed with fibromyalgia.

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. For further information see http://www.JazzPharmaceuticals.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements, including, but not limited to, statements related to the continued development of Jazz Pharmaceuticals' JZP-6 product candidate for the treatme
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials
2. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
3. Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
4. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
5. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
6. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
7. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
8. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
9. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
10. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
11. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014 A pharmaceutical executive in ... with three issues he wanted the research and consulting ... external personnel (especially for secondary research) to maximize efficiency ... of increased workload , Automation of market research ... , How to implement and manage those automated ...
(Date:9/19/2014)... 19, 2014  Today DePuy Synthes Companies of ... plating systems featuring its proprietary variable angle locking ... trajectory to match patient anatomy and fracture pattern ... The systems are being introduced in conjunction with ... and the International Federation of Foot & Ankle ...
(Date:9/19/2014)... 2014 "Copay coupons," a drug ... brand drugs among patients with prescription drug coverage, may now ... new report  from the Department of Health ... (OIG). Federal anti-kickback laws prohibit suppliers from offering side-payments ... by the federal government. The ...
Breaking Medicine Technology:In Era of Competing Needs, Market Research Groups Under Pressure to Utilize Automation and External Staffing 2DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 2DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 3PCMA: New OIG Report Cites Drug Manufacturer "Copay Coupon" Use in Medicare Part D 2
(Date:9/19/2014)... 19, 2014 BearCom, a nationwide ... detailed the key role played by instant, one-to-one ... the healthcare industry. , “In healthcare, speed ... – and in emergency situations, can save precious ... and death,” said Hugh Johnston, Product & Purchasing ...
(Date:9/19/2014)... -- As kids transition from elementary to middle school, ... a recent study. But the researchers studying ... verbal and physical bullying declines as students get older. ... strategies must address all types of bullying as well ... researchers said. The study was published recently in ...
(Date:9/19/2014)... NY (PRWEB) September 19, 2014 On ... News at the Platinum PR and Top Places to ... in New York City. Camino received honorable mentions in ... Campaign” — for its work elevating Latina voices in ... incredible organization and be a part of its efforts ...
(Date:9/19/2014)... More than half of human cancers have ... yet how these signals are controlled during tumor ... PhD, MD, and Svetlana Fayngerts, PhD, both researchers ... at the Perelman School of Medicine, University of ... described oncogenic protein, promotes cancer by targeting these ...
(Date:9/19/2014)... AZ (PRWEB) September 19, 2014 Hastings and ... 30 years in the industry, announces a record number of ... handles a wide variety of serious injury cases as well ... along with dog bite related accident cases and others. Having ... and Hastings has stood the test of time when it ...
Breaking Medicine News(10 mins):Health News:BearCom Releases Guidelines on Using Two-Way Radios to Improve Communications and Enhance Patient Service in Healthcare 2Health News:BearCom Releases Guidelines on Using Two-Way Radios to Improve Communications and Enhance Patient Service in Healthcare 3Health News:BearCom Releases Guidelines on Using Two-Way Radios to Improve Communications and Enhance Patient Service in Healthcare 4Health News: Cyberbullying Seems to Ramp Up in Middle School 2Health News:Camino Public Relations Honored for Raising Latina Voices in National Health Care, Immigration Debates 2Health News:New cancer drug target involving lipid chemical messengers 2Health News:Hastings And Hastings Announces a Record Number of Visitors to Its New Phoenix Personal Injury Website 2
... Mercedes Walton, CEO of Cryo-Cell International, one of the ... progress to date and encouraging continued momentum for existing bills through ... Cord Blood Banking Act," and H.R. 2107, the "Cord Blood Education ... progress from the first half of the year to enable and ...
... Sociological Association,s 104th annual meeting, will be the subject ... present research and explore the politics, history, health and ... More than 5,000 sociologists will convene in the ... New Politics of Community," the meeting,s theme. In addition ...
... , SAN DIEGO, July 6 ADVENTRX Pharmaceuticals, Inc. ... it has completed the previously announced sale of shares ... to a registered direct offering to a single institutional ... percent, or approximately $340,250, of the gross proceeds will ...
... showed muscle fiber damage even after halting drugs, researchers say ... used to lower cholesterol, may cause structural damage to the ... study has found. , The damage may occur even when ... and may persist even after statin use is halted, according ...
... Eli Lilly and Company (NYSE: LLY ) will ... Wednesday, July 22, 2009. Lilly will also conduct a conference ... further detail the company,s financial performance. , , The ... EDT. Investors, media and the general public can access a ...
... Inc. (Nasdaq: SLTM ), a global leader in ... an amendment with Silicon Valley Bank, a member company of ... the company,s credit facility has been expanded from $9 million ... the secured revolving loan facility to $8.0 million, an amendment ...
Cached Medicine News:Health News:Stem Cell Industry Expert Praises, Encourages Continued Progress on Legislation to Promote Benefits of Cord Blood 2Health News:Stem Cell Industry Expert Praises, Encourages Continued Progress on Legislation to Promote Benefits of Cord Blood 3Health News:Sociologists to turn the sociological eye on San Francisco 2Health News:ADVENTRX Pharmaceuticals Announces Closing of Financing 2Health News:ADVENTRX Pharmaceuticals Announces Closing of Financing 3Health News:ADVENTRX Pharmaceuticals Announces Closing of Financing 4Health News:Statins May Cause Muscle Damage in Some Patients 2Health News:Statins May Cause Muscle Damage in Some Patients 3Health News:Solta Medical, Inc. Signs Amendment to Expand Its Credit Facility With Silicon Valley Bank 2Health News:Solta Medical, Inc. Signs Amendment to Expand Its Credit Facility With Silicon Valley Bank 3
... Advanced Magnetics' oral gastrointestinal imaging agent used ... from other abdominal structures and physiology. MRI ... abdomen without contrast agents is difficult because ... distinguished from the loops of the bowel. ...
... only isosmolar contrast medium (IOCM) available in the ... blood, VISIPAQUE was designed for patient safety and ... formulated with sodium and calcium in a ratio ... approval for use in children over one year ...
The Mitek Restore System, designed in conjunction with Sanford S. Kunkel, M.D., offers instrumentation for all ACL Procedures....
Hand surgery basic instrument set...
Medicine Products: